Telomir Pharmaceuticals已正式向美国食品药品监督管理局提交了其候选药物Telomir-1(亦称为Telomir-Zn)的新药临床试验申请。该申请旨在评估该药物在治疗晚期及转移性三阴性乳腺癌患者中的潜力。这一进展标志着公司在推进其创新疗法方面迈出了关键一步。
Telomir Pharmaceuticals已正式向美国食品药品监督管理局提交了其候选药物Telomir-1(亦称为Telomir-Zn)的新药临床试验申请。该申请旨在评估该药物在治疗晚期及转移性三阴性乳腺癌患者中的潜力。这一进展标志着公司在推进其创新疗法方面迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.